Moderna (NASDAQ:MRNA) Shares Gap Down – What’s Next?

Shares of Moderna, Inc. (NASDAQ:MRNA) gapped down prior to trading on Monday . The stock had previously closed at $35.53, but opened at $33.88. Moderna shares last traded at $33.38, with a volume of 3,066,453 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Finally, Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Price Performance

The company has a fifty day moving average price of $37.89 and a 200 day moving average price of $52.10. The company has a market cap of $12.62 billion, a PE ratio of -3.57 and a beta of 1.59.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last three months. 15.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently modified their holdings of the company. Arkadios Wealth Advisors lifted its position in Moderna by 2.2% in the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after buying an additional 243 shares during the last quarter. Knuff & Co LLC raised its stake in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after acquiring an additional 244 shares in the last quarter. Stephens Inc. AR lifted its holdings in shares of Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after acquiring an additional 245 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares during the last quarter. Finally, Howard Capital Management Inc. boosted its stake in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.